ArticleThe ISME journal2025
Targeting Catenibacterium mitsuokai with icariin modulates gut microbiota and improves hepatic lipid metabolism in intrauterine growth restriction.
Article in The ISME journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Article
- Icariin Enhances the Enzymatic Activity of N-acetylgalactosaminidase to Augment Akkermansia Abundance in Gut Microbiota for Improved PD-1 Blockade Efficacy in Tumor Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Subtype-associated gut microbial taxa and their clinical correlates in acute ischemic stroke: comparison of large-artery atherosclerosis and small-vessel occlusion.Frontiers in microbiology · 2026Article
- Transdermal Delivery of Chinese Medicinal Formula Mitigates Pediatric Constipation by Modulating Intestinal Endocrine and Metabolic Homeostasis.Biomaterials research · 2026Article
- The gut-liver axis in animal diseases: roles, mechanisms, and veterinary clinical applications.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Male offspring with intrauterine growth restriction (IUGR) exhibit more pronounced hepatic lipid metabolism abnormalities than females, necessitating earlier intervention. Icariin (ICA) has been shown to effectively modulate hepatic lipid metabolism in male piglets with IUGR. However, the role of gut microbiota in this process remains to be elucidated. This study aimed to explore the influence of gut microbiota on ICA-induced enhancement of hepatic lipid metabolism. By examining changes in microbiota composition and hepatic lipid metabolism following ICA intervention, the study demonstrated an association between microbial alterations and hepatic lipid regulation through fecal microbiota transplantation. The impact of Catenibacterium on gut microbiota structure and hepatic lipid metabolism was assessed in vivo, and the direct effect of ICA on Catenibacterium was explored in vitro. Results revealed that ICA intervention modified fecal, ileal, and colonic microbiota in male piglets with IUGR, enhanced gut morphology and barrier function, and normalized the expression of hepatic peroxisome proliferator-activated receptor signaling pathway-related genes. Fecal microbiota transplantation from piglets with IUGR impaired intestinal barrier function and led to hepatic lipid deposition, whereas transplantation from ICA-treated donors showed no pathological changes, an outcome associated with reduced abundance of Catenibacterium. Mechanistically, ICA inhibits adenosine triphosphate synthesis to suppress Catenibacterium, remodels gut microbiota, reduces lipopolysaccharide production and translocation, and activates the hepatic PPARα/CD36 axis. In conclusion, ICA intervention alleviates hepatic lipid metabolic disorders in male offspring with IUGR by suppressing Catenibacterium, restoring gut microbial balance, and enhancing intestinal barrier integrity to limit lipopolysaccharide translocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.